M A S Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.90 M
- Company Age 20 Year, 2 Months
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 2.40 Cr
- Satisfied Charges ₹ 1.00 Cr
- Revenue Growth -32.82%
- Profit Growth 363.89%
- Ebitda -9.31%
- Net Worth 0.50%
- Total Assets -1.09%
About M A S Pharmaceuticals
M A S Pharmaceuticals Private Limited (MASPPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 December 2004 and has a history of 20 years and two months. Its registered office is in Punjab, Punjab.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.90 M.
The company currently has active open charges totaling ₹2.40 Cr. The company has closed loans amounting to ₹1.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Monika Sood and Sanjay Kumar serve as directors at the Company.
Company Details
-
LocationPunjab, Punjab
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51397PB2004PTC027688
-
Company No.
027688
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
03 Dec 2004
-
Date of AGM
29 Sep 2018
-
Date of Balance Sheet
31 Mar 2018
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at M A S Pharmaceuticals?
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Monika Sood | Director | 03-Dec-2004 | Current |
Sanjay Kumar | Director | 29-Aug-2022 | Current |
Financial Performance of M A S Pharmaceuticals.
M A S Pharmaceuticals Private Limited, for the financial year ended 2018, experienced significant reduction in revenue, with a 32.82% decrease. The company also saw a substantial improvement in profitability, with a 363.89% increase in profit. The company's net worth moved up by a moderate rise of 0.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of M A S Pharmaceuticals?
In 2018, M A S Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹24.00 M
₹10.00 M
Charges Breakdown by Lending Institutions
- Bank Of Baroda : 1.40 Cr
- State Bank Of Patiala : 1.00 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
18 Jan 2007 | Bank Of Baroda | ₹1.40 Cr | Open |
18 Dec 2004 | State Bank Of Patiala | ₹1.00 Cr | Open |
18 Dec 2004 | State Bank Of Patiala | ₹1.00 Cr | Satisfied |
How Many Employees Work at M A S Pharmaceuticals?
Unlock and access historical data on people associated with M A S Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of M A S Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped M A S Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.